In recent years the anti-CD19/anti-CD3 bispecific antibody blinatumomab and chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown early efficacy in clinical trials of paediatric and adult B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4],\ [@bib5]^ The rationale behind targeting CD19 in BCP-ALL is primarily its homogenous cell surface expression and B-lineage specificity.^[@bib5]^ Thus, the entire malignant cell population should be targeted and eradicated by anti-CD19-directed immunotherapies. CD19 would be expected to have important functions in BCP-ALL survival, based on its roles in enhancing pre-B-cell receptor (pre-BCR) mediated phosphoinositide 3-kinase (PI3K) signalling and through pre-BCR-independent pathways such as MYC activation.^[@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ However, the effects of CD19 depletion on BCP-ALL cells have not been investigated. Hence, we examined the role of CD19 in leukaemic maintenance by silencing its expression in BCP-ALL cell lines and primograft samples using RNA interference.

First, we explored the effects of CD19 knockdown in CD19^+^ BCP-ALL cell lines reflecting three maturation stages of BCP-ALL: pro-B-ALL SEM (CD10^−^CD19^+^), common B-ALL REH (CD10^+^CD19^+^) and pre-B-ALL 697 (CD10^+^CD19^+^cyIgM^+^). BCP-ALL cell lines were transduced with two different lentiviral constructs targeting CD19. A short hairpin RNA (shRNA) that specifically targets the fusion gene *RUNX1/ETO* without affecting endogenous RUNX1 was used as a control,^[@bib10]^ as this fusion is not found in any of the cell lines or primografts used (see [Supplementary Methods](#sup1){ref-type="supplementary-material"} for further details). We chose the pTRIPZ system, which allows doxycycline-mediated induction of shRNA) expression and puromycin selection of successfully transduced cells. Five days after induction, CD19 surface expression was reduced 15-fold in SEM cells, sixfold in REH cells and 14-fold in 697 cells by the best construct (shCD19II) compared to the geometric mean of expression in the control ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The CD19 depletion was maintained over several time points ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). None of the cell lines showed any impairment in proliferation over 23--26 days ([Figure 1a](#fig1){ref-type="fig"}) or doubling times: SEM (control: 34 h vs shCD19: 33 h), REH (control: 38 h vs shCD19: 34 h) and 697 (control: 30 h vs shCD19: 29 h). This suggests that, at the level of knockdown achieved, CD19 is not essential for the proliferation of BCP-ALL cell lines in suspension culture.

We next considered that CD19 could be important for niche interactions, so we used a murine stromal cell feeder layer to mimic this. Cells were grown on M2-10B4 cells in medium containing 2% fetal bovine serum, which was the level at which the SEM and 697 cells developed dependence on the feeder layer for growth at low cell densities (10^4^ cells/ml) ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). REH cells did not develop feeder dependence to the same extent as the other cell lines. Next, we performed a competitive assay under these conditions. We seeded equal mixtures of transduced and un-transduced cell populations to determine whether CD19-depleted cells were at a competitive disadvantage to wild-type cells. The ratio of RFP^+^ (shRNA-expressing) to RFP^−^ (wild-type) cells was used to assess changes in the proportions of each population. We did not observe any substantial differences in the ratio of CD19^−^ to wild-type cells for any of the three cell lines studied ([Figure 1b](#fig1){ref-type="fig"}), indicating that CD19 expression does not give cells a competitive growth advantage when adherent on stroma cells.

We also studied the effects of CD19 silencing in a high-risk pre-B-ALL t(17;19) primograft, L707, achieving a threefold reduction in CD19 expression using a constitutively active pGIPZ-shCD19 construct ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). L707 cells were cultured on a human mesenchymal stem cell feeder layer and assessed for cell proliferation after puromycin selection. CD19-depleted L707 cells did not exhibit impaired growth compared to control cells ([Figure 1c](#fig1){ref-type="fig"}) and were not at a competitive disadvantage compared to control cells ([Figure 1d](#fig1){ref-type="fig"}). This suggests that CD19 is not required for leukaemic maintenance in primary blasts.

In support of our *in vitro* data, we obtained a patient sample taken at relapse (LK194), which presented as CD19^+^ BCP-ALL but relapsed as CD19^−^ BCP-ALL after treatment with blinatumomab ([Figures 2a and b](#fig2){ref-type="fig"}, [Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). To investigate if these CD19^−^ cells could engraft and reconstitute leukaemia and if the CD19^−^ phenotype is stable *in vivo*, we injected 1 × 10^6^ CD19^−^ primary cells each into three NOD/LtSz-scid IL-2Rγ null (NSG) mice. All mice presented enlarged spleens (0.56--1.05 g, compared to \<0.1 g for non-engrafted mice) and histological analysis showed leukaemic infiltration of the bone marrow ([Supplementary Figure 6](#sup1){ref-type="supplementary-material"}). Fluorescence-activated cell sorting analysis of harvested spleen samples showed that CD19^−^ blasts were able to engraft and reconstitute the leukaemia, and that the phenotype appeared stable ([Figures 2c and e](#fig2){ref-type="fig"}, [Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). In one mouse ([Figure 2d](#fig2){ref-type="fig"}), a CD19^+^ population also emerged. These cells were also evident in CD19-stained histological sections ([Supplementary Figures 6C and D](#sup1){ref-type="supplementary-material"}). To investigate the relative repopulating ability of these populations, we re-transplanted the primograft into secondary recipients. In three secondary mice, the CD19^+^ peak appeared to increase in size relative to the CD19^−^ cells, suggesting the CD19^+^ blasts have a slight advantage in repopulating ability *in vivo* ([Figure 2f](#fig2){ref-type="fig"}, [Supplementary Figure 8](#sup1){ref-type="supplementary-material"}). However, a defined CD19^+^ population did not emerge in a secondary transplant of one of the CD19^−^ primografts ([Figure 2g](#fig2){ref-type="fig"}), demonstrating that the blasts are not dependent on CD19 for survival *in vivo*. It is unclear whether the CD19^+^ cells grew from a pre-existing minor CD19^+^ subclone in the relapsed sample, or arose from the CD19^−^ population through re-expression of CD19. A recent study has demonstrated exon 2 skipping as a mechanism of resistance to anti-CD19 therapeutics, whereby cells express a truncated CD19 protein to evade detection by anti-CD19 CAR T cells.^[@bib11]^ Analysis of LK194 primograft using reverse transcriptase-PCR demonstrated expression of a transcript containing exons 1--3, with no evidence of exon 2 skipping ([Figure 2h](#fig2){ref-type="fig"}). Moreover, sequencing confirmed that the CD19 cDNA from LK194 was fully intact, compared with both a reference transcript and cDNA from the SEM cell line ([Supplementary Figure 9](#sup1){ref-type="supplementary-material"}). The presence of full-length CD19 transcript in these cells, but absence of protein, demonstrates evidence of an alternative mechanism of resistance to T-cell therapies to that previously described.^[@bib11]^ Further investigation of the mechanisms by which this occurs will be important for understanding how to circumvent the development of resistance to anti-CD19 therapies in patients.

In summary, we have shown that BCP-ALL cell lines and primary blasts are not dependent on CD19 for survival and propagation in both *in vitro* and *in vivo* settings. This is contrary to the expectation given the functions of CD19 in pre-BCR and PI3K signalling and suggests that CD19-independent pathways play an important role in BCP-ALL development. Further investigation of the differences between CD19^+^ and CD19^−^ ALL blasts will be important to understand these pathways. Our data are consistent with other studies reporting CD19^−^ leukaemias^[@bib12],\ [@bib13]^ and demonstrating the emergence of CD19^−^ BCP-ALL clones following therapies targeting CD19.^[@bib3],\ [@bib4]^ Similarly, immature CD34^+^/CD19^−^ cells from primary high-risk paediatric ALL samples have previously been shown to engraft and maintain leukaemia in immunodeficient mice.^[@bib14]^ It is therefore evident that leukaemic blasts that lose expression of the CD19 antigen will be able to survive and escape CD19-targeted therapies, increasing the risk of CD19^−^ relapse. It remains to be seen how big an impact this will have on the long-term efficacy of CD19 immunotherapies. Thus, in the future it will be vital to identify how best to integrate these immunotherapies into standard treatment protocols^[@bib15]^ and develop combination therapies to eliminate emergent CD19^−^ blasts.
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![CD19 knockdown in BCP-ALL cell lines and high-risk BCP-ALL primograft does not affect cell growth. (**a**) Cell growth of BCP-ALL cell lines transduced with two different shRNA constructs targeting CD19 or RUNX1/ETO (control) in suspension culture. (**b**) CD19-depleted cells are not disadvantaged in a competitive setting. Populations of untransduced BCP-ALL cell lines and cells transduced with a pTRIPZ shRNA construct were mixed at low cellular density under serum-starved conditions on feeder cells. Relative tRFP expression represents the proportion of cells expressing the construct. The graph shows the mean of two independent experiments. (**c**) Cell growth of BCP-ALL primograft (L707) transduced with pGIPZ shRNA constructs against CD19 or RUNX1/ETO on human mesenchymal stem cell (hMSC) feeder cells in comparison with untransduced cells. Cell numbers were equalised at the first timepoint to allow comparison of growth rates. (**d**) Competitive assay of BCP-ALL primograft transduced with CD19 or RUNX1/ETO constructs mixed with untransduced BCP-ALL primograft on hMSC feeder cells. The graph shows the change in proportion of GFP-positive to -negative cells over the time course. The GFP-positive cells correspond to the fraction expressing the construct.](leu201664f1){#fig1}

![The CD19^−^ BCP-ALL sample is able to engraft NSG mice. Histogram showing CD19 expression in a relapsed CD19− sample LK194 (**a**) compared to a typical ALL diagnostic sample (**b**). (**c-e**) CD19 expression in spleen samples from mice transplanted with LK194, harvested 10 weeks post transplant. The green line shows cells labelled with B-cell surface markers CD10, CD34, CD58, human-specific CD45 and mouse-specific CD45. This acts as a control for the pink histogram, which shows cells labelled with these same cell surface markers but with the addition of CD19. Only human cells are shown. See also [Supplementary Figures 5 and 7](#sup1){ref-type="supplementary-material"}. **(f**, **g)** CD19 expression in spleens of mice transplanted with samples from Mouse 2 (**f**) or Mouse 3 (**g**). See also [Supplementary Figure 8](#sup1){ref-type="supplementary-material"} (**h**). Gel electrophoresis image of PCR products to detect the expression of CD19 exons 1--3, using cDNA from LK194 mouse samples. Arrows show expression of CD19 transcript containing exons 1--3 (403 bp) and absence of the variant that skips exon 2 (expected size 137 bp). SEM cells were used as a CD19^+^ control. NTC, non-template control.](leu201664f2){#fig2}
